uniQure (QURE) Finished Goods (2022 - 2023)
uniQure's (QURE) quarterly Finished Goods came in at $758000.0 in Q4 2023, down 48.29% year-on-year from $1.5 million in Q4 2022, and down 53.53% quarter-over-quarter from $1.6 million in Q3 2023.
uniQure (QURE) Finished Goods (2022 - 2023) Analysis & Trends
uniQure's Finished Goods history runs 2 years deep, the most recent figure standing at $758000.0 for Q4 2023.
- On a quarterly basis, Finished Goods fell 48.29% year-over-year to $758000.0 in Q4 2023; TTM through Dec 2023 was $758000.0, a 48.29% decrease from a year earlier, with the FY2023 full-year figure at $758000.0, down 48.29% from the prior year.
- Finished Goods retreated to $758000.0 in Q4 2023 per QURE's latest filing, from $1.6 million in the prior quarter.
- Across five years, Finished Goods topped out at $1.6 million in Q3 2023 and bottomed at $140000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | uniQure | 2.43 Bn | 2.43 Bn | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 758,000.00 |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 140,000.00 |
| Dec 31, 2022 | 1.47 Mn |
| Sep 30, 2022 | 450,000.00 |